Media

Nordic Nanovector and Affibody collaborate on advanced radio-immunotherapies program for Multiple Myeloma

GLIONOVA RECEIVES SEK 5 MILLION GRANT FROM SWEDISH INNOVATION AGENCY VINNOVA

WILSON THERAPEUTICS ANNOUNCES START OF PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF WTX101 IN NEWLY DIAGNOSED WILSON DISEASE PATIENTS

GLIONOVA THERAPEUTICS SECURES SEK 42 MILLION ($5.7 MILLION) CO-LEAD BY HEALTHCAP AND NOVO TO TAKE NOVEL THERAPY FOR GLIOBLASTOMA INTO CLINIC

Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update

Onxeo Quarterly Information as of September 30, 2014

AEROCRINE AB RECEIVES US FDA MARKET CLEARANCE FOR NIOX VERO®

Nexstim Plc successfully completes its Initial Public Offering – subscriptions reach EUR 15.3 million with final offer price of EUR 6.35 per share

Nordic Nanovector strengthens management team to prepare for its next phase